Tag: Iovance

Iovance Biotherapeutics finds itself at a critical juncture as it prepares for significant investor conferences in early September. These events ...

Iovance Biotherapeutics' stock experienced significant selling pressure after the company revealed plans to raise up to $350 million through a ...

Iovance Biotherapeutics finds itself navigating a complex landscape, achieving significant medical breakthroughs with its innovative cancer therapies while simultaneously facing ...

Biopharmaceutical firm Iovance Biotherapeutics has unveiled plans to raise $350 million through an at-the-market equity offering, a move that has ...

Iovance Biotherapeutics has achieved a significant regulatory milestone with Health Canada granting market authorization for its T-cell immunotherapy, Amtagvi (lifileucel). ...

Iovance Biotherapeutics has achieved a significant industry milestone, becoming the first company to secure Canadian regulatory approval for a T-cell ...

Iovance Biotherapeutics is experiencing a significant market revaluation following a major regulatory development north of the border. Health Canada has ...

Shares of Iovance Biotherapeutics surged in after-hours trading following a pivotal regulatory win in Canada. Health Canada granted conditional approval ...